Valuing Your Emerging Biotech Lead Asset to Attract Investors

Valuing Your Emerging Company’s Lead Asset to Attract Investors

Most preclinical to Phase 1 emerging biotech executive teams underestimate the importance of defining the intrinsic value of their lead asset(s). Unfortunately, potential investors are quick to recognize this oversight, which can significantly undermine credibility.
Determining an asset’s value in the future commercial marketplace is critical for internal portfolio prioritization and crafting a compelling investor story. And if the value simply isn’t there, it’s time to stop pursuing that asset in that indication.
During this 50-minute live microcourse, we’ll guide you through the essential components and proven framework for determining intrinsic value.

Takeaways

1. Understand the concept of defensible revenue forecasting and the key assumptions that support sound projections.
2. Gain insight into competitive intelligence strategies that shape accurate market valuation.
3. Explore the potential impact of the Inflation Reduction Act (IRA) on drug development programs.